| Catalog No. |
TD-VK565266 |
| Species reactivity |
SARS-CoV-2 (2019-nCoV) |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1, lambda2 |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P0DTC2-2 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
BMS986413,BMS-986413,BMS986413,C-144-LS,CAS:2599039-61-7 |
| Background |
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |
抗体
试剂盒
多肽
探针
蛋白
组织芯片
定制服务咨询